Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BMS, Pfizer Discontinue Apixaban Development for ACS
December 6, 2010
- Shionogi Leads IP Assets Ranking Followed by Kyowa Kirin
December 6, 2010
- Kyowa Kirin to Present KW-0761 Results at ASH
December 6, 2010
- Janssen Resumes Supply of Velcade
December 6, 2010
- BI Publishes Dabigatran Sub-Group Analysis
December 6, 2010
- Popular Name Made Legal Name: InCROM
December 6, 2010
- OncoTherapy Starts Clinical Trial for Gastric Tumor Vaccine
December 6, 2010
- NHI Pricing Recommended for Xyzal, Byetta
December 6, 2010
- PAFSC Withholds Recommending Switch OTC Version of Epadel
December 6, 2010
- Memantine, Galantamine Recommended for Approval for AD
December 6, 2010
- Yasuchika Hasegawa to Be Appointed Chairman of Keizai Doyukai
December 6, 2010
- Takeda's SONIAS Recommended for Approval
December 6, 2010
- Kobayashi: Sales Up 0.8% despite Rebound from Boom for Flu-related Products in Previous Year
December 6, 2010
- Janssen's Stelara Recommended for Approval
December 6, 2010
- Cawachi: Sales, Profits Show Only Slight Increases
December 6, 2010
- 2-Week Limit on Prescription to Be Lifted for 4 ARB/CCB Combination Drugs
December 6, 2010
- Bayer Schering to Apply for Rivaroxaban in US, Europe by Year End: Chairman Andreas Fibig
December 6, 2010
- Sales, Profits Up for 3 Leading Dispensing Pharmacy Chains
November 29, 2010
- Taiyo: Profits Down Due to Business Suspension
November 29, 2010
- Sekisui Chemical Acquires Diagnostics Business from Genzyme
November 29, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…